Commodore Capital LP Trims Stock Position in Mind Medicine (MindMed) Inc. $MNMD

Commodore Capital LP cut its position in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) by 38.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,000,000 shares of the company’s stock after selling 1,225,000 shares during the period. Mind Medicine (MindMed) makes up 1.8% of Commodore Capital LP’s holdings, making the stock its 23rd biggest holding. Commodore Capital LP’s holdings in Mind Medicine (MindMed) were worth $26,780,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in MNMD. Concurrent Investment Advisors LLC purchased a new stake in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $273,000. UBS Group AG raised its stake in shares of Mind Medicine (MindMed) by 23.9% in the 4th quarter. UBS Group AG now owns 683,802 shares of the company’s stock valued at $9,156,000 after acquiring an additional 131,993 shares during the period. Jennison Associates LLC purchased a new stake in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $720,000. PSP Research LLC purchased a new stake in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $467,000. Finally, Royce & Associates LP raised its stake in shares of Mind Medicine (MindMed) by 102.5% in the 4th quarter. Royce & Associates LP now owns 164,041 shares of the company’s stock valued at $2,197,000 after acquiring an additional 83,017 shares during the period.

Mind Medicine (MindMed) Price Performance

Mind Medicine (MindMed) stock opened at $0.69 on Thursday. The business’s 50-day moving average price is $0.69.

Mind Medicine (MindMed) (NASDAQ: MNMD) is a clinical-stage biotechnology company focused on developing psychedelic-inspired medicines and accompanying therapeutic protocols to treat mental health disorders and substance use disorders. The company’s research emphasizes both novel small molecules and established psychedelic compounds used in controlled, clinically supervised settings, with the goal of creating safe, scalable treatments that combine pharmacology with psychotherapy.

MindMed’s activities include preclinical research, clinical trials, and the development of treatment delivery models and protocols that integrate drug administration with therapeutic support.